Recent Updates
Recently added Catalysts
SGHT Positive Sentiment Score: 75/100

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Key Takeaway: Sight Sciences, Inc. (Nasdaq: SGHT) announced its participation at the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3, 2024, in New York. The presentation will be accessible through a live and archived webcast on the company's investor website. Sight Sciences specializes in developing interventional technologies aimed at enhancing eye care, particularly through minimally invasive solutions for conditions like glaucoma and dry eye disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sight Sciences will present at a prominent healthcare conference, increasing visibility.
  • The company's innovative technologies aim to improve the standard of eye care.
  • The presentation could attract potential investors and partnerships.

Full Press Release Details

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY.
Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: investors.sightsciences.com.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.

Frequently Asked Questions

When will Sight Sciences present at the Healthcare Conference?

Sight Sciences will present on December 3, 2024, at 12:30 pm PT.

How can I access the Sight Sciences presentation?

Access the live and archived webcast on the company's Investors section.

What does Sight Sciences focus on?

Sight Sciences focuses on developing innovative eyecare technologies to improve patient care.

What is the OMNI® Surgical System used for?

The OMNI® Surgical System is for reducing intraocular pressure in glaucoma patients.

What is the purpose of the TearCare® System?

The TearCare® System applies heat therapy to treat evaporative dry eye disease.

Last updated: Nov 19, 2024